Comparative Pharmacology
Head-to-head clinical analysis: LOTRISONE versus OXISTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOTRISONE versus OXISTAT.
LOTRISONE vs OXISTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lotrisone combines betamethasone dipropionate, a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, and clotrimazole, an imidazole antifungal that inhibits CYP51 (lanosterol 14alpha-demethylase), disrupting ergosterol synthesis and fungal cell membrane integrity.
Oxiconazole is an azole antifungal that inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Apply a thin film to affected skin areas twice daily, morning and evening, for 2 weeks.
Apply topically once daily for 2 weeks (tinea pedis, tinea cruris, tinea corporis) or 4 weeks (tinea versicolor).
None Documented
None Documented
Clotrimazole: 3.5-6 hours (topical, minimal systemic absorption); betamethasone dipropionate: approximately 4-6 hours for betamethasone after hydrolysis.
Terminal elimination half-life is 20–30 hours, supporting once-daily topical application.
Clotrimazole: <0.5% of dose excreted unchanged in urine; betamethasone dipropionate: primarily renal (<5% unchanged) and biliary/fecal (35-50% as metabolites).
Primarily hepatic metabolism; <1% excreted unchanged in urine; biliary/fecal elimination accounts for ~75% of dose.
Category C
Category C
Topical Antifungal/Corticosteroid Combination
Topical Antifungal